Oxitropium bromide
Chemical compound
- R03BB02 (WHO)
- (8r)-6β,7β-Epoxy-8-ethyl-3α-hydroxy-1αH,5αH-tropanium bromide (−)-tropate
- 30286-75-0
- 16735948
- SF4NW7NH7C
- ChEMBL1697846
- DTXSID0023402
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- [Br-].OC[C@H](c1ccccc1)C(=O)O[C@@H]2C[C@@H]3[C@H]4O[C@H]4[C@H](C2)[N+]3(C)CC
InChI
- InChI=1S/C19H26NO4.BrH/c1-3-20(2)15-9-13(10-16(20)18-17(15)24-18)23-19(22)14(11-21)12-7-5-4-6-8-12;/h4-8,13-18,21H,3,9-11H2,1-2H3;1H/q+1;/p-1/t13-,14-,15-,16+,17-,18+,20?;/m1./s1
- Key:LCELQERNWLBPSY-KHSTUMNDSA-M
Oxitropium bromide (trade names Oxivent, Tersigan) is an anticholinergic used as a bronchodilator for the treatment of asthma and chronic obstructive pulmonary disease.[1]
It was patented in 1966 and approved for medical use in 1983.[2]
Synthesis
The natural product, norscopolamine (1),[3] is converted by two alkylation reactions into oxitropium bromide. The first, with bromoethane, gives the N-ethyl intermediate (2), which is treated with bromomethane.[4] [5][6]
References
- ^ Restrepo RD (July 2007). "Use of inhaled anticholinergic agents in obstructive airway disease". Respiratory Care. 52 (7): 833–51. PMID 17594728.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 447. ISBN 9783527607495.
- ^ Ripperger, H (1995). "(S)-scopolamine and (S)-norscopolamine from Atropanthe sinensis". Planta Med. 61 (3): 292–3. doi:10.1055/s-2006-958082. PMID 7617778.
- ^ Rolf Banholzer, Werner Schulz, Gerhard Walther, Helmut Wick, Karl Zeile, U.S. patent 3,472,861 (1969 to Boehringer Sohn Ingelheim).
- ^ Rolf Banholzer, Werner Schulz, & Karl Zeile, U.S. patent 3,538,102 (1970 to CH Boehringer Sohn AG and Co KG, Boehringer Ingelheim GmbH).
- ^ "Oxitropium bromide". Thieme. Retrieved 2024-07-01.
- v
- t
- e
Short-acting β2 agonists | |
---|---|
Long-acting β2 agonists |
|
Ultra-long-acting β2 agonists | |
Other |
muscarinic antagonist
Leukotriene antagonists | |
---|---|
Arachidonate 5-lipoxygenase inhibitors | |
Thromboxane receptor antagonists | |
Non-xanthine PDE4 inhibitors |
- Aclidinium bromide/formoterol
- Beclometasone/formoterol
- Beclometasone/formoterol/glycopyrronium bromide
- Budesonide/formoterol
- Budesonide/glycopyrronium bromide/formoterol
- Fluticasone furoate/umeclidinium bromide/vilanterol
- Fluticasone furoate/vilanterol
- Fluticasone propionate/salmeterol
- Glycopyrronium bromide/formoterol
- Indacaterol/glycopyrronium bromide
- Indacaterol/glycopyrronium bromide/mometasone
- Indacaterol/mometasone
- Ipratropium bromide/salbutamol
- Mometasone/formoterol
- Salbutamol (albuterol)/budesonide
- Umeclidinium bromide/vilanterol
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e